Reshaping Pharmacovigilance in the Age of AI
Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.
Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, joins Miranda Schmalfuhs to discuss:
- His career background and current role
- Indegene's new study Reshaping Pharmacovigilance in the Age of AI
- What's holding the industry back from artificial intelligence/machine learning adoption
- How to keep/utilize existing employees when adopting AI/ML technologies
- Current automations trends
- Where the industry is headed
About the speaker
Sameer Lal holds a bachelor of science degree and a bachelor of science (technology) degree, both from University of Mumbai and master of management studies degree from the Narsee Monjee Institute of Management Studies, Mumbai. He has 25+ years of experience in pharmaceutical industry and technology-led healthcare solutions provider sector. Prior to joining Indegene, Inc., he was associated with GlaxoSmithKline Pharmaceuticals Limited, Ranbaxy Laboratories Limited and Sudler & Hennessey Private Limited.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
